Poster Presentation 31st Lorne Cancer Conference 2019

High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma  (#359)

Sewa Rijal 1 , Johanna Kok 2 , Caitlin Coombes 2 , Lilian Smyth 1 , Dipti Talaulikar 1 2 3
  1. Australian National University Medical School, Canberra, ACT, Australia
  2. Department of Hematology, Canberra Hospital, Canberra, ACT, Australia
  3. John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia

Diffuse large B cell lymphoma (DLBCL) is the commonest lymphoma that is highly aggressive where one-third of the patients relapse despite effective treatment. Tumor microenvironment that involves interaction between the malignant cells and the immune cells and is thought to play a critical role in the pathogenesis of DLBCL. Our aim was to characterize the proportion of total B cells and various B-cell subpopulations in the bone marrow (N=47) and peripheral blood (N=54) of 75 DLBCL patients at diagnosis and study their impact on survival. High proportion of anergic B cells in bone marrow (>13.9%) characterized as having CD21(-/low)/CD38- expression by flow cytometry, was found to be associated with significantly shorter overall survival (p =0.020). Moreover, Cox regression analysis in our cohort of patients revealed that it was an independent poor prognostic marker, alongside the established Revised International Prognostic Index score.